Atrial fibrillation (AF) is the most common arrhythmia diagnosed in clinical practice and often treated with pulmonary veins isolation (PVI). This procedure has both high bleeding and thromboembolic risk therefore well evidenced anticoagulation protocols are important. Anticoagulation strategy in patients undergoing PVI is described Expert Consensus. We analyzed studies released after 2018 pertaining to anticoagulation during PVI. Different anticoagulation approaches for AF ablation were studied. New evidence on edoxaban and apixaban for PVI emerged. Direct oral anticoagulants (DOACs) seemed to be safer in terms of bleeding risk and equally effective in stroke prevention compared to vitamin K antagonists (VKAs). Uninterrupted and interrupted anticoagulation strategies with NOACs were studied and brought conflicting results. “Dabigatran bridge” strategy for PVI was tested. New knowledge on occurrence and clinical significance of silent brain ischemia lesions after PVI was described. Alternative heparin dosing strategy during PVI in patients on NOACs was proposed.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.